Category Reports Biotech

Tickers reports and analysis

ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real

Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.”

Artiva Biotherapeutics Inc ( $ARTV ) March 11th

Artiva Biotherapeutics rallied sharply after its full-year 2025 results and business update put the spotlight back where biotech traders care most: near-term clinical readouts, FDA path visibility, analyst support, and whether the balance sheet is strong enough to carry the story into the next real value-inflection point.

Hims & Hers ( $HIMS ) from GLP-1 backlash to a big strategic reset

A few weeks ago the core question was whether Hims had pushed the GLP-1 trade too far and invited a regulatory and legal backlash that could damage one of the market’s favorite growth stories. That question has not disappeared. But the story has changed meaningfully. The company now has a formal strategic shift in U.S. weight loss, a public collaboration with Novo Nordisk, access to branded Wegovy and Ozempic on the platform, a dropped lawsuit, and still the pending Eucalyptus acquisition that could reshape the company from a fast U.S. telehealth operator into a broader global consumer-health platform.

Ocugen Inc ( $OCGN ) why the stock exploded, what the dual analyst boost really means

Ocugen came back to life on a violent session after a stacked sell-side day: one firm initiated with an Outperform and a $10 target, while another raised its target to $22 from $15 and kept a Buy rating. But the move does not sit on analyst language alone. It lands on top of a Phase 3 enrollment-complete lead program, a visible BLA path, multiple ocular follow-on catalysts, a high-beta retail base, meaningful short interest, and a balance sheet that is improved from panic but still nowhere near bulletproof.

ImmunityBio (NASDAQ: IBRX) — FDA resubmission

What happened today
Today’s real headline is straightforward: ImmunityBio announced that it has resubmitted the supplemental biologics license application to the FDA for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.

According to the company, it had already submitted information requested by the FDA in February 2026, but in March the agency then requested updated efficacy information based on longer follow-up, which ImmunityBio says has now been included in the resubmitted package.

IMMP under halt: what may really be behind it ( $IMMP )

Immutep’s Nasdaq-listed ADRs were halted on Friday, March 6, 2026 under code T1 / News Pending. On the Australian side, the public halt notice points to an announcement regarding the outcome of the pre-specified interim futility analysis for the Phase III TACTI-004 trial. That single detail matters a lot: it shifts the center of gravity from wild speculation to a very specific clinical event. What follows is a structured look at the facts, the company, the pipeline, and the full range of plausible scenarios.

Weekly Recap & Briefing – Oil Shock, Weak Jobs, Iran War and a More Selective Tape (Mar 2–6, 2026)

The week that closed on Friday 6 March was the first full trading week in which markets had to process the new Middle East war regime rather than just react to a weekend headline. The U.S.–Israeli campaign against Iran and the retaliation that followed kept energy, shipping and inflation risk at the centre of the tape, while the S&P 500 ended the week lower, the VIX climbed to its highest level since April 2025 and Brent crude pushed above 90 dollars a barrel. On top of that, Friday’s U.S. jobs report added a second layer of stress: payrolls unexpectedly fell and the unemployment rate moved up, pushing investors into an awkward mix of growth fear and inflation fear at the same time.

PMV Pharmaceuticals Inc ( $PMVP )

PMV Pharmaceuticals is a precision oncology company built around rezatapopt (PC14586), an oral small-molecule reactivator of p53 designed for tumors harboring the TP53 Y220C mutation. The story matters because TP53 is one of the most important tumor suppressor genes in cancer biology, and because PMV has now moved from mechanism-only interest into clinically visible efficacy data. The company’s registrational PYNNACLE study has produced an overall 34% ORR across evaluable Phase 2 patients and a 46% ORR in the ovarian cohort at the September 4, 2025 cutoff, with the company later reporting a 50% ORR in the same ovarian cohort after that cutoff. FDA Orphan Drug Designation granted on March 2, 2026 adds meaningful regulatory support. PMV says it plans to submit an NDA in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.

Obesity Medicines 2026 — Part 1: sector map for investors

A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares.

Obesity Medicines 2026 Part 2

Part 2 moves from the sector to the stocks themselves. Each company is examined through the same lens: ticker, core asset, stage, regulatory standing, commercial position, why the market cares, bull case, bear case and the next likely stock-moving issues. The goal is not to crown a winner but to show what each public name really is today.

Three March PDUFAs retail biotech traders are watching most closely

March is packed with biotech catalysts, but for many retail traders the shortlist comes down to three names: Lantheus, Aldeyra and Rocket Pharmaceuticals. They are very different stories — one radiopharma platform name, one dry-eye binary, one rare-disease gene-therapy approval setup — but all three have the ability to move fast around FDA timing, market expectations and headline interpretation.

Atara Biotherapeutics (ATRA): after the new tabelecleucel update, a second attempt at an FDA path 

Two months after the FDA’s complete response letter on tabelecleucel for EBV+ PTLD, Atara and partner Pierre Fabre are back in Washington with a Type A meeting request and a thick briefing book. The goal is simple but ambitious: convince the agency that the data set behind EBVALLO, already approved in Europe, can still support a viable U.S. path despite the sudden change of tone on the ALLELE trial.

Verastem Oncology ( $VSTM )

First commercial year for AVMAPKI FAKZYNJA CO-PACK in KRAS-mutant LGSOC delivered $30.9M in net product revenue, Japan’s RAMP 201J bridged exposure and responses in both KRAS-mutant and wild-type disease, and management now promises a self-sustaining LGSOC franchise by 2H 2026 — with RAMP 301 confirmatory data only in mid-2027.